{"preliminary_commentary":{"by_channel":{"x_thread":42,"youtube":15,"podcast":11,"x_video":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03975647\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"HER2CLIMB-02","nct_id":"NCT03975647","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=her2climb-02-nct03975647. The price is an estimate of verified HCP statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified HCP statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Tucatinib + T-DM1","label":"Tucatinib + T-DM1","type":"EXPERIMENTAL"},{"description":"Placebo + T-DM1","label":"Placebo + T-DM1","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-03-10","type":"ESTIMATED"},"conditions":["HER2-positive Breast Cancer"],"enrollment":{"count":466,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"tucatinib","otherNames":["ONT-380"],"type":"DRUG"},{"name":"placebo","otherNames":[],"type":"DRUG"},{"name":"T-DM1","otherNames":["Kadcyla"],"type":"DRUG"}],"last_update":"2026-07-23","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","official_title":"Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-06-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment","timeFrame":"From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)"}],"references":[{"citation":"Hurvitz SA, Loi S, O'Shaughnessy J, Okines AFC, Tolaney SM, Sohn J, Saura C, Zhu X, Cameron D, Bachelot T, Hamilton E, Curigliano G, Wolff AC, Harbeck N, Masuda N, Vahdat L, Zaman K, Valdes-Albini F, Block M, Pluard T, Tan TJ, Gawryletz C, Chan A, Bedard PL, Yerushalmi R, Xu B, Schmitt M, Xie D, Borges VF; HER2CLIMB-02 study investigators. Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02. Ann Oncol. 2026 Mar;37(3):341-352. doi: 10.1016/j.annonc.2025.11.005. Epub 2025 Nov 17.","pmid":"41260264","type":"DERIVED"}],"start_date":{"date":"2019-10-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer","url":"https://clinicaltrials.gov/study/NCT03975647"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/her2climb-02-nct03975647"}